Ro-3306

Name: Ro-3306
Brand: Selleck Chemicals
SKU: S7747
Rating: 5 (77 reviews)

For research use only.

Catalog No.S7747

77 publications

CAS No. 872573-93-8

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.

Selleck's Ro-3306 has been cited by 77 publications

Nature, 2016, 539(7627):54-58

PubMed: 27760120 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(20)30951-5

PubMed: 33453166 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3760

PubMed: 34145295 ( click the link to review the publication )

Nat Struct Mol Biol, 2021, 28(6):487-500

PubMed: 34117478 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108840

PubMed: 33730584 ( click the link to review the publication )

PLoS Pathog, 2021, 17(5):e1009580

PubMed: 33974675 ( click the link to review the publication )

Cancer Discov, 2021, candisc.1540.2020

PubMed: 33941591 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(11)5706

PubMed: 34071893 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00485-3

PubMed: 33895139 ( click the link to review the publication )

STAR Protoc, 2021, 2(3):100495

PubMed: 34195669 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-162979/v1

PubMed: None ( click the link to review the publication )

EMBO J, 2021, e106336

PubMed: 33595114 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-162979/v1

PubMed: N/A ( click the link to review the publication )

Cell Res, 2020, 10.1038/s41422-020-0357-y

PubMed: 32561861 ( click the link to review the publication )

Mol Cell, 2020, 22 pii: S1097-2765(20)30231-8

PubMed: 32353258 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4338

PubMed: 32859893 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1819

PubMed: 32286328 ( click the link to review the publication )

EMBO J, 2020, 2;e104036

PubMed: 32484965 ( click the link to review the publication )

Dev Cell, 2020, 55(6):707-722.e9

PubMed: 33321102 ( click the link to review the publication )

Genes Dev, 2020, 1;34(9-10):650-662

PubMed: 32217664 ( click the link to review the publication )

EMBO Rep, 2020, e48686

PubMed: 32484300 ( click the link to review the publication )

Cancer Res, 2020, 20 pii: canres 883 2019

PubMed: 32312836 ( click the link to review the publication )

Cell Rep, 2020, 32(11):108140

PubMed: 32937135 ( click the link to review the publication )

Cell Rep, 2020, 32(9):108080

PubMed: 32877684 ( click the link to review the publication )
Cell Death Differ, 2020, 10.1038/s41418-020-00641-7

PubMed: 33110216 ( click the link to review the publication )

Cancers (Basel), 2020, 24;12(4) pii: E1054

PubMed: 32344689 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):E1637

PubMed: 32575711 ( click the link to review the publication )

Cells, 2020,

PubMed: 32846968 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12882

PubMed: 33320980 ( click the link to review the publication )

Cell Discov, 2020, 28;6:26

PubMed: 32351706 ( click the link to review the publication )

Cell Transplant, 2020, 29:963689720950226

PubMed: 32841050 ( click the link to review the publication )

Gland Surg, 2020, 9(2):558-574

PubMed: 32420291 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):180

PubMed: 32152291 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32033461 ( click the link to review the publication )

J Cell Sci, 2020, 133(14):jcs243857

PubMed: 32591484 ( click the link to review the publication )

Neuroendocrinology, 2020, 10.1159/000509865

PubMed: 32615570 ( click the link to review the publication )

Viruses, 2020, 6;12(3):289

PubMed: 32155766 ( click the link to review the publication )

Development, 2020, 147(13):dev184838

PubMed: 32620578 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Mol Cell, 2019, 75(2):267-283

PubMed: 31202576 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2253

PubMed: 31138795 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz602

PubMed: 31291454 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1915108116

PubMed: 31712441 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(27):13374-13383

PubMed: 31209037 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31484670 ( click the link to review the publication )

Cell Rep, 2019, 26(4):955-968.e3

PubMed: 30673617 ( click the link to review the publication )
Elife, 2019, 8e44161

PubMed: 30860482 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

FASEB J, 2019, 33(4):5334-5349

PubMed: 30668924 ( click the link to review the publication )

J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Open Biol, 2019, 9(8):190136

PubMed: 31455158 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4511

PubMed: 30375385 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2171-2178

PubMed: 29438989 ( click the link to review the publication )

J Biol Chem, 2018, 293(40):15524-15537

PubMed: 30135207 ( click the link to review the publication )

FEBS Lett, 2018, 592(11):1893-1904

PubMed: 29782647 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30545129 ( click the link to review the publication )

Cancer research, 2018, 10.1158/0008-5472.CAN-17-2288

PubMed: ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201801369R

PubMed: 30496702 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2039

PubMed: 29229926 ( click the link to review the publication )

Elife, 2017, 6e30523

PubMed: 29106372 ( click the link to review the publication )

Oncogene, 2017, 36(44):6177-6189

PubMed: 28869606 ( click the link to review the publication )

EBioMedicine, 2017, 19:18-30

PubMed: 28434945 ( click the link to review the publication )

Sci Rep, 2017, 7:44464

PubMed: 28290553 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(20)

PubMed: 28760773 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )

Sci Rep, 2017, 7:41950

PubMed: 28176818 ( click the link to review the publication )
Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Arthritis Rheumatol , 2016, 68(5):1222-32

PubMed: 26663909 ( click the link to review the publication )

Cell Cycle, 2016, 15(20):2742-52

PubMed: 27580187 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0149099

PubMed: 26881434 ( click the link to review the publication )

J Cell Biol, 2015, 209(2):221-34

PubMed: 25918224 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Targets

CDK1 ^[1] (Cell-free assay)	PKCδ ^[1] (Cell-free assay)	SGK ^[1] (Cell-free assay)	ERK ^[1] (Cell-free assay)
20 nM(Ki)	318 nM(Ki)	497 nM(Ki)	1980 nM(Ki)

In vitro

RO-3306 inhibits CDK1/cyclin B1, CDK1/cyclin A, CDK2/cyclin E, and CDK4/cyclin D activity with Ki of 35 nM, 110 nM, 340 nM, and over 2000 nM, respectively. Treatment of HCT116, SW480, and HeLa cells with RO-3306 for 20 h leads to a complete block of the cell cycle in the G2/M phase. The proliferation of both HCT116 and SW480 is effectively blocked by RO-3306. RO-3306 appears to be more proapoptotic in cancer cells (HCT116 and SW480) than nontumorigenic cells (MCF 10A and MCF 12A).^[1] RO-3306 effectively arrests oocyte maturation at a concentration of 10 μM.^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
KB-3-1 adenocarcinoma cell line	NHj2[Y5yUFSVIHHzd4F6		MXXQMYdtgWOxcILveIVqdiC\|dXLzeJJifGW\|IHnk[Y51cW[rZXSgbY4hU0JvMz2xJIFl\W6xY3HyZ4lvd22jIHPlcIwhdGmwZTygdWhVWyC2aHXyZZBmfXSrYzDsbYJz[XK7IIPjdoVmdg>?	NEDkcow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUWxOVI5PCd-M{G1NVUzQDR:L3G+
human H460a cells	M1HhN3Bzd2yrZnXyZZRqd25iYYPzZZk>		NXK0bXV{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIOFYx[SClZXzsd{whUUN3ME2xMlA1KM7:TR?=	NH7mfHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OwN\|QzOSd-MUezNFM1OjF:L3G+
human MDA435 cells	MUXQdo9tcW[ncnH0bY9vKGG\|c3H5		NVfGWGNRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGE1OzViY3XscJMtKEmFNUC9NU4yPCEQvF2=	MmC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|MEO0NlEoRjF5M{CzOFIyRC:jPh?=
human HCT116 cells	NUC1OXpYWHKxbHnm[ZJifGmxbjDhd5NigQ>?		Ml\QRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOsJGlEPTB;MT6xOEDPxE1?	M{H6NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{CzOFIyLz5zN{OwN\|QzOTxxYU6=
human RKO cells	M2L5[XBzd2yrZnXyZZRqd25iYYPzZZk>		M{\SfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUlvPJINmdGy\|LDDJR\|UxRTJizszN	NHnKUXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OwN\|QzOSd-MUezNFM1OjF:L3G+
human SW480 cells	M1TxRnBzd2yrZnXyZZRqd25iYYPzZZk>		NVi4[HpoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTW\|Q5OCClZXzsd{whUUN3ME2yMlIh\|ryP	NGLqSWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OwN\|QzOSd-MUezNFM1OjF:L3G+
human SJSA1 cells	NV;F[owxWHKxbHnm[ZJifGmxbjDhd5NigQ>?		NInidWdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPKV2EyKGOnbHzzMEBKSzVyPUSuOVUh\|ryP	M1nYUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{CzOFIyLz5zN{OwN\|QzOTxxYU6=
human HCT116 cells	MoKyR5l1d3SxeHnjxsBie3OjeR?=	MWe1JIRigXN?	MnfoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFUh\GG7czDifUBOXFNiYYPzZZnwxIxiSVO1NF0{NjJizszN	M1HYW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{K2NVY5Lz5{MkOyOlE3QDxxYU6=
NCI-SNU-1	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHr5eVRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD63N\|A6PSEQvF2u	NV;IeGdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
H4	MnfRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzLkG1PFc2KM7:TT6=	M2HV[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
PA-1	M2nXWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3X0N2lvcGmkaYTpc44hd2ZiaIXtZY4hWEFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU4zOjZ3NDFOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
T98G	NYPiO\|VlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFO2UG9KdmirYnn0bY9vKG:oIHj1cYFvKFR7OFegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvOzZ6MUKg{txONg>?	M{XV[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
SW1710	MnzOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NH[1WoJKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS54MUSwPEDPxE1w	MmTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
U251	MkniS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV3QTnk3UW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjZ\|N{exJO69VS5?	MlfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
ALL-PO	NGfWcpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1OzXGlvcGmkaYTpc44hd2ZiaIXtZY4hSUyOLWDPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjlyOEGzJO69VS5?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SK-N-DZ	NFHrbmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXPuWI1YUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{LkCxPFc3KM7:TT6=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
A4-Fuk	NVvTdXIzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlnFTY5pcWKrdHnvckBw\iCqdX3hckBCPC2IdXugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIvODV4MESg{txONg>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
639-V	Mm\yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWPpSoVJUW6qaXLpeIlwdiCxZjDoeY1idiB4M{mtWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOi5{N{WzO{DPxE1w	M1v5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
Hs-578-T	Mm\rS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFHRNo1KdmirYnn0bY9vKG:oIHj1cYFvKEi\|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{LkK3O\|k6KM7:TT6=	NU\aenJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
UM-UC-3	M1[2Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEnWbIxKdmirYnn0bY9vKG:oIHj1cYFvKFWPLWXDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwN{O5N\|Yh\|ryPLh?=	MoHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
BPH-1	MlTtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXXJcohq[mm2aX;uJI9nKGi3bXHuJGJRUC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlk4PDV3IN88UU4>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
5637	M{jq[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NH7hT4VKdmirYnn0bY9vKG:oIHj1cYFvKDV4M{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMvODh3M{Kg{txONg>?	NV[yZ4U2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
8-MG-BA	MkLvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mk\4TY5pcWKrdHnvckBw\iCqdX3hckA5NU2JLVLBJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjF2MES5JO69VS5?	Mnf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnjqTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|LkKzOVAyKM7:TT6=	Ml7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
KOSC-2	MmrGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEnINoFKdmirYnn0bY9vKG:oIHj1cYFvKEuRU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy52NE[2NkDPxE1w	M37kcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
COR-L88	M1vCTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmezTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjR5NUizJO69VS5?	NHzWOYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
PSN1	NGTQZ4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVHIdoFZUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1NjFyOEC1JO69VS5?	MoLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
LXF-289	M1L2fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mnr2TY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1NjJzN{[g{txONg>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
MN-60	M3qwZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIHmZmVKdmirYnn0bY9vKG:oIHj1cYFvKE2QLU[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1NjN5NkKzJO69VS5?	MlvlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NEC8	MmD4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1HFNGlvcGmkaYTpc44hd2ZiaIXtZY4hVkWFODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE41PzB5NjFOwG0v	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H2405	Ml\GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFXufHJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlQxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iND63OFQ6OyEQvF2u	NHLuVIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
YH-13	MnrmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUT2NXFqUW6qaXLpeIlwdiCxZjDoeY1idiC\SD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPC55NUe3OkDPxE1w	NFyxTGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SK-MEL-2	NFvhU5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M37JXGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDVwMEm2N\|Ih\|ryPLh?=	MnizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NB13	NXfiTY5wT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmnDTY5pcWKrdHnvckBw\iCqdX3hckBPSjF\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC1MlMzPzh4IN88UU4>	NEexNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
GAMG	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NI\6NXJKdmirYnn0bY9vKG:oIHj1cYFvKEeDTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvOzdzNTFOwG0v	NITCTm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NCI-H1792	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkDpTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDVwNEe5OVQh\|ryPLh?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
KP-4	M4j4SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYnJcohq[mm2aX;uJI9nKGi3bXHuJGtRNTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEWuOlk5OjNizszNMi=>	MlXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
HGC-27	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnSzTY5pcWKrdHnvckBw\iCqdX3hckBJT0NvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvPzNyN{eg{txONg>?	MmrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
GCT	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlvoTY5pcWKrdHnvckBw\iCqdX3hckBIS1RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEWuPFUyOjFizszNMi=>	NWPuUVNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
PFSK-1	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2XLOmlvcGmkaYTpc44hd2ZiaIXtZY4hWE[VSz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2Njh4MU[4JO69VS5?	Mn7PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
A172	M3HsWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Moe4TY5pcWKrdHnvckBw\iCqdX3hckBCOTd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC1MlkxPzlizszNMi=>	NYDMN244RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HO-1-N-1	Mne2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGhQNTFvTj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2Njl3NEK1JO69VS5?	MlLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
HN	NVzheWt5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4LKSGlvcGmkaYTpc44hd2ZiaIXtZY4hUE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEWuPVcxQTdizszNMi=>	NXnJWZJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
IST-MES1	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NH3ncopKdmirYnn0bY9vKG:oIHj1cYFvKEmVVD3NSXMyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB3Lkm3OVIyKM7:TT6=	NWDufVRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
TGW	NF70W5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkCwTY5pcWKrdHnvckBw\iCqdX3hckBVT1diY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IE[uNFU3QDJizszNMi=>	NWLBPI5ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
COR-L23	Mo\FS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoXSTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA3NjN5M{Wg{txONg>?	M4XmNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
D-566MG	Ml\3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2jHbWlvcGmkaYTpc44hd2ZiaIXtZY4hTC13Nk\NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPi55OEi3N{DPxE1w	MojoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SKG-IIIa	MmGwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlTLTY5pcWKrdHnvckBw\iCqdX3hckBUU0dvSVnJZUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPi56NUW3NkDPxE1w	NUPHVVh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NCI-H446	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEG0fodKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOFQ3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB5LkCxPFEh\|ryPLh?=	MnXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
KYSE-270	NX[4WXNPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MULJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvMkewJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4NjB\|OEeyJO69VS5?	M3HLclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
CAL-39	NEO0cGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{HHcmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4NjN3MkSg{txONg>?	MkGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
IST-SL1	NFLvPHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmDTTY5pcWKrdHnvckBw\iCqdX3hckBKW1RvU1yxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4NjR\|M{S5JO69VS5?	NUjuN2xiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
SF539	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVPJcohq[mm2aX;uJI9nKGi3bXHuJHNHPTN7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC3MlU2OTl5IN88UU4>	NU[4RYpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
TE-1	Mmi3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGK3blNKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFcvQDlyOUGg{txONg>?	MkjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NB10	M3\aUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHzj[JlKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFcvQTh5NUig{txONg>?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
8505C	NUDudWUzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXr5WIRHUW6qaXLpeIlwdiCxZjDoeY1idiB6NUC1R{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPy57OUixO{DPxE1w	M1L0dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
DB	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4LafGlvcGmkaYTpc44hd2ZiaIXtZY4hTEJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEiuNFEyOzFizszNMi=>	MlvkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H28	NHjqcHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4LsfGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQC53OUi4OEDPxE1w	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
LOXIMVI	M4j6RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUS1fXI5UW6qaXLpeIlwdiCxZjDoeY1idiCOT2jJUXZKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB6Lk[zO\|AyKM7:TT6=	NHraPVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
ME-180	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M13EU2lvcGmkaYTpc44hd2ZiaIXtZY4hVUVvMUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA5NjhyM{m1JO69VS5?	NGPocI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
ES3	Mn3kS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUXm[mR2UW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFkvOTJ5OUSg{txONg>?	NIPMSYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SK-N-FI	NHi0SZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4W4dmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3GTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQS52MU[5PUDPxE1w	M{nPTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NBsusSR	MljLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Ml3sTY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOC5{M{G4JO69VS5?	MoXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
GI-ME-N	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGG3UoRKdmirYnn0bY9vKG:oIHj1cYFvKEeLLV3FMW4h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFyLkK3PFMh\|ryPLh?=	NXTDU5l4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
A704	M1;OUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmG5TY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNE4{OzF6IN88UU4>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HuP-T4	M3rMVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXTJcohq[mm2aX;uJI9nKGi3bXHuJGh2WC2WNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvPDJ5MTFOwG0v	NGjvOnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
A101D	M1PjUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGT4OGhKdmirYnn0bY9vKG:oIHj1cYFvKEFzMEHEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS5zNUe0JO69VS5?	NEPDUJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
MCF7	Mm\4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEH2[mhKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjF6NEmg{txONg>?	NHHmdG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
A549	M2nzV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFLHZlhKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjJyNjFOwG0v	Mk\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
HD-MY-Z	MmCxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{W3RmlvcGmkaYTpc44hd2ZiaIXtZY4hUERvTWmtXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTFwMkC2JO69VS5?	M1:yXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HCC1395	NUPKRo5RT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUDrUlkyUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN\|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMT61OVk3KM7:TT6=	NIfJUIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SK-NEP-1	NWLWV4I{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoX2TY5pcWKrdHnvckBw\iCqdX3hckBUUy2QRWCtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTFwN{OzNkDPxE1w	M3zZdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HSC-2	M2K5UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml7DTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVEvPzh2MjFOwG0v	NF7ORoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HCC1937	M4rhTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGhESzF7M{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjh2N{Og{txONg>?	NGTn[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
RS4-11	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M17qfWlvcGmkaYTpc44hd2ZiaIXtZY4hWlN2LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS56OEO2JO69VS5?	M3iwTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
CAL-27	Mn72S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXHJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVIvOTZ\|NzFOwG0v	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H23	MmXXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkjRTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOi52MUW1JO69VS5?	M1jkUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
A431	Mme1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYHFS21ZUW6qaXLpeIlwdiCxZjDoeY1idiCDNEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOi55MkOzJO69VS5?	NF3XbXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HT-1080	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFS1OFZKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{LkezO\|Mh\|ryPLh?=	M2PwUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
GB-1	MmTIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnHvTY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNk44PzF4IN88UU4>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
BFTC-909	M2TnN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYnJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOy5zME[4JO69VS5?	NHrEbnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
CAL-33	NYrLS4xvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M175cWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUOzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOy54NUG4JO69VS5?	M2HaclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
JVM-3	M4HoXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGnZbHZKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPC5{NkK3JO69VS5?	Mn;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
AN3-CA	MnXpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXzJcohq[mm2aX;uJI9nKGi3bXHuJGFPOy2FQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVQvQTV5ODFOwG0v	NULDclAxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
VM-CUB-1	M3jIPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{P0d2lvcGmkaYTpc44hd2ZiaIXtZY4hXk1vQ2XCMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF3LkGzOlQh\|ryPLh?=	MkT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
A253	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIi0SXpKdmirYnn0bY9vKG:oIHj1cYFvKEF{NUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE2NjJ6M{Sg{txONg>?	NV75SZlLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
RPMI-7951	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHLrVIdKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtO\|k2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMU[uNVk5OSEQvF2u	M1O1N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NCI-H1563	NWXrWmI5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{WxcmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzNj64NlU{KM7:TT6=	NEjBOJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
LB831-BLC	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVrCfW1UUW6qaXLpeIlwdiCxZjDoeY1idiCOQkizNU1DVENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEG3MlE6OjlizszNMi=>	NEXQOnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
ES8	M3jMPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWPrOJV1UW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE4NjNzNUeg{txONg>?	M17PeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NCI-H292	NEPQeZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFHKfY9KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzNz60O\|Q6KM7:TT6=	NGHGTZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
OAW-42	NE\P[WtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVi1[mJSUW6qaXLpeIlwdiCxZjDoeY1idiCRQWetOFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF5Lki4NlMh\|ryPLh?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
RCC10RGB	MkThS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXPQb\|NqUW6qaXLpeIlwdiCxZjDoeY1idiCUQ1OxNHJISiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUeuPVU4QCEQvF2u	NVnTZ4ZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
PC-3	NFjKblFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHvKTJZKdmirYnn0bY9vKG:oIHj1cYFvKFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE5NjByNEOg{txONg>?	NYXW[XF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HCC38	Mk\HS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYXJcohq[mm2aX;uJI9nKGi3bXHuJGhESzN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxPE4yODNzIN88UU4>	NFntNnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
DEL	MnjMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYfJcohq[mm2aX;uJI9nKGi3bXHuJGRGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUiuN\|g4KM7:TT6=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
ABC-1	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVvJcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxPE42PjJ5IN88UU4>	M3\ZSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
SW756	NG\QU5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2XvUmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5NU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE6NjF\|NUGg{txONg>?	MnjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
TE-6	MlzjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3TPd2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVkvOjFyMzFOwG0v	NH;LR3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
H-EMC-SS	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmXqTY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTlwNEO1PUDPxE1w	MlvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
HCT-116	M375Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlvsTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQS54Nkig{txONg>?	M{nTOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
CHP-212	NEjleHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlP5TY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQS55NEe4JO69VS5?	M3XHRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
SK-LU-1	NVjRRWRRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUPyflhsUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzOT63OVMh\|ryPLh?=	NEiyWnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HT-3	NFjmd2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH7lW2tKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIxNjB{ODFOwG0v	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
KG-1	M1;jfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFjZd\|FKdmirYnn0bY9vKG:oIHj1cYFvKEuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIxNjJyNjFOwG0v	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
ES1	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWLJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkGuNFA1QCEQvF2u	MorXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYrq[XhDUW6qaXLpeIlwdiCxZjDoeY1idiCUYX3vd{0zTzZvNFOxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjFwN{e1OkDPxE1w	NFv4eFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
IA-LM	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1[xdmlvcGmkaYTpc44hd2ZiaIXtZY4hUUFvTF2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIyNjl4OUSg{txONg>?	M1H5[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
BHT-101	NHPWSopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHvu[GZKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ{LkC2Nlkh\|ryPLh?=	M4m0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
OVCAR-4	NYX4b4VFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUjJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIzNjR5IN88UU4>	M3y1dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
SW1573	MlK1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGHIVnpKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUW3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjJwN{mzOEDPxE1w	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
CHL-1	Mkm2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGO4e5BKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOy5{OEOzJO69VS5?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
BFTC-905	M4HTTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mk\xTY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjNwMki5NkDPxE1w	NX;sd4p6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
TE-12	M1y4fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWfjcIZ6UW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjNwNUe4NkDPxE1w	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H358	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIm4dZRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IN\|U5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Mz62OFc4KM7:TT6=	NHXDd4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
OVCAR-5	Ml;KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYDESI9FUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{ND6xNFQh\|ryPLh?=	NEnjN5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
CGTH-W-1	M1jJZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGTzVnRKdmirYnn0bY9vKG:oIHj1cYFvKEOJVFitW{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{NT6wPFA1KM7:TT6=	NEDjTJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SNU-423	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFjMN4tKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT20NlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ3LkO2OkDPxE1w	NWS4SXN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
CP50-MEL-B	NF3Ne3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmG1TY5pcWKrdHnvckBw\iCqdX3hckBEWDVyLV3FUE1DKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{NT63N\|k6KM7:TT6=	MlrJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H2087	NXzLOmVpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmH0TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ3Lki2OVUh\|ryPLh?=	MorBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
RMG-I	M4PnUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3fCbWlvcGmkaYTpc44hd2ZiaIXtZY4hWk2JLVmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI2Njl{MUmg{txONg>?	NX7nTlhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
KP-N-YS	M1r3emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmHZTY5pcWKrdHnvckBw\iCqdX3hckBMWC2QLWnTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPi5{MEKg{txONg>?	Ml3nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
OMC-1	M4nQO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXu3[GRkUW6qaXLpeIlwdiCxZjDoeY1idiCRTVOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjZwNUC4JO69VS5?	NU\LW2UxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
DMS-114	NWOxe\|c1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NET2SWpKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2xNVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ5LkO5OlYh\|ryPLh?=	MlT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SHP-77	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUHJcohq[mm2aX;uJI9nKGi3bXHuJHNJWC15NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlcvPDh6IN88UU4>	M2S1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
MPP-89	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXW2ZWNKUW6qaXLpeIlwdiCxZjDoeY1idiCPUGCtPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ5Lkm0N\|gh\|ryPLh?=	MlnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H1581	NIDXTnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MV;Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW4NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjhwNEWzOUDPxE1w	NIjNUZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
D-283MED	M4TIRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUfJTo5pUW6qaXLpeIlwdiCxZjDoeY1idiCGLUK4N21GTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkiuOFY4PCEQvF2u	NX7wWXV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
MOLT-4	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXHJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlgvQTB5MjFOwG0v	M1X2OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
ES6	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV;CXY12UW6qaXLpeIlwdiCxZjDoeY1idiCHU{[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI6NjZ2M{[g{txONg>?	M2DIfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NB6	NXLNfW05T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkT1TY5pcWKrdHnvckBw\iCqdX3hckBPSjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK5Mlg3OzhizszNMi=>	MorsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SW954	MmnwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGrQZndKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzQS57NEC3JO69VS5?	NUTsfHhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
A388	M2K5XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NY[yOGdIUW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzQS57NEKyJO69VS5?	M3n3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
OAW-28	NEn0OYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXfibnhUUW6qaXLpeIlwdiCxZjDoeY1idiCRQWetNlgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNyLkKyO\|gh\|ryPLh?=	MmDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SK-MES-1	NHvXNnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFzOTHFKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|MT6yNlA5KM7:TT6=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H441	M4[zcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWrMZWhwUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ1OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iM{GuPVg3QCEQvF2u	MkPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
HOP-92	M2faPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1\wfWlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SLUmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Oi5{M{W2JO69VS5?	NY\RSo9jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NB14	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEO5XpNKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMzNjd{NUGg{txONg>?	M1XK[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
MS-1	NETWcHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGPTdWdKdmirYnn0bY9vKG:oIHj1cYFvKE2VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMzNjd4MESg{txONg>?	MkjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
YKG-1	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXLJcohq[mm2aX;uJI9nKGi3bXHuJHlMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzNk45OzN4IN88UU4>	NYfOPJo1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
SiHa	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4nDUmlvcGmkaYTpc44hd2ZiaIXtZY4hW2mKYTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|MvOzh{OTFOwG0v	NVHxXFQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HAL-01	M2\vWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1PkPWlvcGmkaYTpc44hd2ZiaIXtZY4hUEGOLUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PC5{M{e2JO69VS5?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
Ca-Ski	MmDRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGNiNVOtaTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|QvPzZ4OTFOwG0v	MmLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H747	NEK3OVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{S3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PC57OEe1JO69VS5?	M3nk[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
KYSE-510	MnvHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PS54NEi1JO69VS5?	MnrEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
A204	MnXCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4nQT2lvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|UvPzJyOTFOwG0v	NVW3[YNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HSC-3	NHjFNHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoDXTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|YvODB6NjFOwG0v	NXLBZlFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HuP-T3	M2\wZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHuyUIlKdmirYnn0bY9vKG:oIHj1cYFvKEi3UD3UN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzZwNEizNkDPxE1w	Mmf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
RPMI-8226	MnjGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYn5ZWxKUW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVgzOjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEO2MlYzODhizszNMi=>	NELiWpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
QIMR-WIL	NUfZSIg3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWHJcohq[mm2aX;uJI9nKGi3bXHuJHFKVVJvV1nMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Pi54NESg{txONg>?	MnjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
HuH-7	NEH5UnlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXPlNVdjUW6qaXLpeIlwdiCxZjDoeY1idiCKdVitO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzhwNkG4OEDPxE1w	NHPlVFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
CAL-12T	NF75cZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVLJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1zMmSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM5Njl2MU[g{txONg>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
GT3TKB	NH;STWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXvlcFBVUW6qaXLpeIlwdiCxZjDoeY1idiCJVEPUT2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN7LkG5NlEh\|ryPLh?=	NWHVSJhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
OC-314	NYH6UFNjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYG0N49MUW6qaXLpeIlwdiCxZjDoeY1idiCRQz2zNVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN7LkexNlUh\|ryPLh?=	NEnaPFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NCI-H2228	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkKyPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDBwMUSwN{DPxE1w	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H727	NH62T\|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIrRb41KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|I4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2MD6yOVMyKM7:TT6=	M{LPfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEfVfmpKdmirYnn0bY9vKG:oIHj1cYFvKE6WRWLBMXMu[2xvREGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQxNjR5ME[g{txONg>?	NYn3cJBYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
MMAC-SF	NVLTcmJ6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlLmTY5pcWKrdHnvckBw\iCqdX3hckBOVUGFLWPGJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OC57MkO1JO69VS5?	NIizdpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HTC-C3	M1\ydGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYjocpJuUW6qaXLpeIlwdiCxZjDoeY1idiCKVFOtR\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRzLkSxOlkh\|ryPLh?=	NHThWIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SF295	NEi5[FlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWHJcohq[mm2aX;uJI9nKGi3bXHuJHNHOjl3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0NU42Ozd7IN88UU4>	MnnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
U-2-OS	NXO2O2tYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXW4SHFxUW6qaXLpeIlwdiCxZjDoeY1idiCXLUKtU3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRzLki1Olch\|ryPLh?=	NInybnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HPAF-II	Mmj6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIKx[FhKdmirYnn0bY9vKG:oIHj1cYFvKEiSQV[tTWkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRzLkmzPFIh\|ryPLh?=	MljBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
KYSE-450	M{Xldmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M33VVGlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT20OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR{LkS3NFch\|ryPLh?=	NIX0dpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
DMS-273	MmP6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmjOTY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Oy5{OEO2JO69VS5?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HT-1376	MoDiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NImxe4JKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGzO\|Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR\|LkOxOVYh\|ryPLh?=	MoruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
786-0	MoftS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmjyTY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFMvPjJ4MTFOwG0v	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H810	NH\OUGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NU\vS2NoUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNESuNFE{PiEQvF2u	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
8305C	NGHKc2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYPpPYljUW6qaXLpeIlwdiCxZjDoeY1idiB6M{C1R{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDRwNkS1JO69VS5?	NFXVdpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
DSH1	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUHKUZJVUW6qaXLpeIlwdiCxZjDoeY1idiCGU1ixJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1PS55MESyJO69VS5?	NUPCSmJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
KYSE-520	NIDzZ3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNUKwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Pi53N{KxJO69VS5?	NE\NS5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
TYK-nu	MlfNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlX2TY5pcWKrdHnvckBw\iCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ3NjdyOUKg{txONg>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
EPLC-272H	NFPYRVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUTycmhNUW6qaXLpeIlwdiCxZjDoeY1idiCHUFzDMVI4OkhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES2MlczQDNizszNMi=>	Mlm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
T-24	M13le2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIT3PVVKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ4Njl{OUKg{txONg>?	MknwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
BHY	NF7DUlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1TVS2lvcGmkaYTpc44hd2ZiaIXtZY4hSki\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0O{46QTlizszNMi=>	NYPOSnllRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NCI-H82	MoPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KOEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ5NjJzNzFOwG0v	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SF268	NYrRTIUyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NV7M[JhFUW6qaXLpeIlwdiCxZjDoeY1idiCVRkK2PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDhwNkG4PUDPxE1w	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
C-33-A	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX\wT3BpUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR6Lke1OVQh\|ryPLh?=	NVTXNJJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
MIA-PaCa-2	NGPFbXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoPhTY5pcWKrdHnvckBw\iCqdX3hckBOUUFvUHHDZU0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2OD64N\|g5KM7:TT6=	NYLlSGtuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HCC1954	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlH5TY5pcWKrdHnvckBw\iCqdX3hckBJS0NzOUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QS5yOEexJO69VS5?	M1u4[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NCI-H1666	MnfIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4W5d2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2OT6zOlQzKM7:TT6=	NFPjNVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
GR-ST	NInITWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUHFbplqUW6qaXLpeIlwdiCxZjDoeY1idiCJUj3TWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDlwM{[5OUDPxE1w	MkDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
Ca9-22	NV3lOpFvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnPMTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ6NjRyMUOg{txONg>?	NGT4PIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
D-502MG	M1q4dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXHJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTB{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ6NjRzNzFOwG0v	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SCC-4	NUTxNGtjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWHJcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0PU42PjB{IN88UU4>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
RKO	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlzITY5pcWKrdHnvckBw\iCqdX3hckBTU09iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES5Mlg{PTZizszNMi=>	NW\nb5A1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Cdk1 / Cdk1 / Cleaved PARP / Cleaved caspase-3 / p-p38 / Bad / Apaf1-1 / p-H2Ax / Bim / Bad; PubMed: 27385216 Oncotarget OVCA-429 and OVCAR-3 were exposed to RO-3306 for 24 h in indicated dose dependent manner, (F) 10 uM RO-3306 for 12 h up to 48 h. The expression level of the indicated protein and the phosphorylated form of H2A.x and p38 were examined via Western blot analyses.	27385216
Immunofluorescence	PARP1 / Plk1 ; PubMed: 28069876 Mol Cancer Ther Representative images of IF staining for PARP1 and Plk1 in 22RV1 cells treated with 0.3 mM mimosine for 20 h, 4 mM hydroxyurea for 24 h, 10 µM RO-3306 for 7 h or 200 ng/ml nocodazole (Noc) for 12 h.	28069876
Growth inhibition assay	Cell viability; PubMed: 27385216 Oncotarget OVCA-429 and OVCAR-3 were exposed to RO-3306 in indicated time- and dose-dependent manner. Cell viability were measured via crystal violet assay. Results are the means ± S.E. n = 3.	27385216

Protocol

Kinase Assay:^[1]

- Collapse

CDK assay:

The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.

Cell Research:^[3]

- Collapse

Cell lines: MDA-MB-231 cell line
Concentrations: 20 μM
Incubation Time: 72 h
Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	13 mg/mL warmed (36.98 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ro-3306 SDF

Molecular Weight	351.45
Formula	C₁₈H₁₃N₃OS₂
CAS No.	872573-93-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC2=C(C=CC(=C2)C=C3C(=O)NC(=NCC4=CC=CS4)S3)N=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
AT7519 HCl ^New

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol (L86-8275) HCl

Flavopiridol HCl (L86-8275, NSC 649890, Alvocidib, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Roscovitine (CYC202)

Roscovitine (CYC202, Seliciclib, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
Abemaciclib mesylate (LY2835219)

Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306